GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mersana Therapeutics
Mersana Therapeutics is a biotech company specializing in antibody-drug conjugates (ADCs) for cancer treatment. Its stock price is driven by news of clinical trials. The chart reflects both the technology's great potential and the setbacks in its development.
Share prices of companies in the market segment - Cancer women
Mersana Therapeutics is an oncology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of ovarian cancer and other gynecological cancers. We have classified the company in the "Women's Cancers" segment. The chart below shows the dynamics in this important biotech segment.
Broad Market Index - GURU.Markets
Mersana Therapeutics is an oncology company developing a new class of targeted therapy—antibody-drug conjugates—for the treatment of cancer. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MRSN - Daily change in the company's share price Mersana Therapeutics
Mersana Therapeutics, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its ovarian cancer treatments.
Daily change in the price of a set of shares in a market segment - Cancer women
Mersana Therapeutics, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with MRSN's dynamics, which depend on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Mersana Therapeutics is a biotech company focused on women's health, particularly cancer treatment. Its shares are highly volatile and dependent on clinical trial results. These scientifically based movements are part of the complex picture of the overall stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mersana Therapeutics
For Mersana Therapeutics, year-over-year performance is a tale of ups and downs in antibody-drug conjugate (ADC) development. Its market cap change over the past 12 months reflects both disappointing data from some programs and hopes for others. Its valuation reflects investors' faith that its unique platform can ultimately lead to a successful drug.
Annual dynamics of market capitalization of the market segment - Cancer women
Mersana Therapeutics, Inc. is a biotechnology company developing a new class of targeted cancer therapies (antibody-drug conjugates). Its stock price is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mersana is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mersana Therapeutics
Mersana Therapeutics is an oncology company developing antibody-drug conjugates (ADCs). Its monthly performance is entirely dependent on the results of its clinical trials. News about the safety and efficacy of its drugs causes sharp fluctuations in its price.
Monthly dynamics of market capitalization of the market segment - Cancer women
Mersana Therapeutics is developing antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. This segment of oncology is one of the hottest. The chart below reflects the intense investor interest in "smart bomb" technology, which delivers chemotherapy directly to the tumor, and their reaction to clinical trial data.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mersana Therapeutics is an oncology company specializing in antibody-drug conjugates (ADCs) for the treatment of cancer in women. Its stock price is entirely dependent on the results of its clinical trials. This represents a high-risk bet on the success of its scientific platform.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mersana Therapeutics
Mersana Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its weekly stock price is highly volatile and depends on clinical trial data, which can be a binary event that determines the company's future and causes sharp price movements.
Weekly dynamics of market capitalization of the market segment - Cancer women
Mersana Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its weekly stock price is highly volatile and depends on clinical trial data, which can be a binary event that determines the company's future and causes sharp price movements.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Mersana, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
MRSN - Market capitalization of the company Mersana Therapeutics
Mersana's market capitalization chart tells the story of the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its dramatic rises and falls reflect all the dramas of biotech: from promising data to trial pauses due to side effects. It's a visualization of the high risk and potential of oncology.
MRSN - Share of the company's market capitalization Mersana Therapeutics within the market segment - Cancer women
Mersana Therapeutics is a clinical-stage biotech developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its market capitalization reflects the potential of its platform. The chart below shows the high valuation volatility associated with clinical trial results.
Market capitalization of the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. The chart below shows the overall market capitalization of the women's cancer sector. It illustrates how ADC technology enables the delivery of powerful chemotherapy directly to tumor cells, increasing efficacy and reducing toxicity.
Market capitalization of all companies included in a broad market index - GURU.Markets
This graph represents precision chemotherapy delivery. Mersana Therapeutics develops antibody-drug conjugates (ADCs) that deliver toxic drugs directly to cancer cells. Its volatile pipeline reflects the successes and failures of clinical trials for this complex but promising technology.
Book value capitalization of the company, segment and market as a whole
MRSN - Book value capitalization of the company Mersana Therapeutics
Mersana Therapeutics' capital is its scientific platform for creating antibody-drug conjugates (ADCs), a new class of anti-cancer drugs. This represents cutting-edge scientific and technological capital. This chart shows how the biotech company, despite setbacks, manages its resources to develop and clinically test its innovative ADCs.
MRSN - Share of the company's book capitalization Mersana Therapeutics within the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its assets are laboratories and patents. The chart shows a minimal share of physical assets, as it is an R&D company whose value lies in its scientific platform.
Market segment balance sheet capitalization - Cancer women
Oncology drug development, as the BCap_Ges chart for biotech shows, is knowledge-intensive. Mersana Therapeutics, with its antibody-drug conjugate platform, invests in science, not manufacturing. Its business is intellectually, not physically, capital-intensive.
Book value of all companies included in the broad market index - GURU.Markets
Mersana Therapeutics' book value represents capital allocated to the development of next-generation antibody-drug conjugates (ADCs). It reflects the financial basis for the creation of "smart bombs" that deliver a toxic payload directly to cancer cells, a complex material product.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mersana Therapeutics
Mersana Therapeutics is developing a new class of cancer drugs (antibody-drug conjugates). Its value lies in its scientific platform. Its book value is low. Its market capitalization is a valuation of its technology and development pipeline. The MvsBCap chart will be very sensitive to clinical trial data, which could either confirm or refute its approach.
Market to book capitalization ratio in a market segment - Cancer women
Mersana Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for cancer treatment. Its value lies in its Dolasynthen platform. The chart shows how the market views its innovative approach to targeted cancer drug development.
Market to book capitalization ratio for the market as a whole
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company's value lies in its unique platform for creating ADCs. Its market valuation reflects the potential of this technology and its developments. The chart shows how investors value scientific innovations in targeted cancer therapy.
Debts of the company, segment and market as a whole
MRSN - Company debts Mersana Therapeutics
Mersana, a clinical-stage biotech developing a new class of drugs (antibody-drug conjugates) for the treatment of cancer, is devoting all of its capital to R&D. This chart shows how the company is funding its complex and expensive research, striving to create more effective and safer treatments for cancer patients.
Market segment debts - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. ADC technology is complex and requires significant investment in R&D and manufacturing. This chart shows how the company is funding its innovative platform and expensive clinical trials in one of the hottest areas of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mersana Therapeutics
Mersana Therapeutics is developing antibody-drug conjugates for the treatment of cancer, particularly ovarian cancer. This chart shows its reliance on debt to finance expensive clinical trials. High debt in biopharma is a high-stakes game: success can bring huge profits, while failure can lead to bankruptcy.
Market segment debt to market segment book capitalization - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs) for targeted cancer therapy. This chart illustrates the debt burden in the oncology biotech sector. It helps understand how the company finances its complex scientific platform and clinical trials, striving to create more effective drugs with fewer side effects.
Debt to book value of all companies in the market
Mersana Therapeutics is a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. The chart below reflects investors' risk appetite. For a company with drugs in clinical trials, access to capital for R&D is a key success factor.
P/E of the company, segment and market as a whole
P/E - Mersana Therapeutics
This chart of Mersana Therapeutics, a company developing a new generation of antibody-drug conjugates, shows the market valuation of its oncology platform. The high valuation reflects investors' belief that its technology will enable more effective delivery of chemotherapy to cancer cells, particularly in the treatment of ovarian cancer.
P/E of the market segment - Cancer women
This chart shows the average P/E ratio for the biotech sector, where Mersana develops oncology drugs. The industry's high valuation reflects hopes for breakthroughs. This ratio serves as a benchmark for assessing how innovative the market perceives Mersana's technology compared to other developments in the field.
P/E of the market as a whole
Mersana Therapeutics develops antibody-drug conjugates (ADCs)—"smart bombs" that deliver powerful chemotherapy directly to cancer cells. The company focuses on treating ovarian cancer. This chart shows biotech sentiment. It helps understand how the market values Mersana's technology platform and how clinical trial data impacts its valuation relative to ADC competitors.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mersana Therapeutics
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. The technology aims to deliver chemotherapy directly to the tumor. This graph demonstrates analysts' confidence that clinical trials will demonstrate the superiority of their ADC platform over existing treatments.
%20P%2FE%20Mersana%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mersana-Therapeutics&v=1772647261528 "Chart of the company's future (projected) P/E Mersana Therapeutics")
Future (projected) P/E of the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment, aiming to improve their efficacy and safety. This chart shows analyst estimates for its future revenue, reflecting confidence in its technology platform and clinical development potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-women&v=1772647261540 "Future (projected) P/E graph of the market segment - Cancer women")
Future (projected) P/E of the market as a whole
Mersana Therapeutics is developing antibody-drug conjugates (ADCs), a cutting-edge cancer treatment. This is a highly competitive and research-intensive field. This chart, reflecting the overall investment climate, impacts valuations and capital availability for all biotech companies. Market optimism allows Mersana to continue its cost-effective research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647261571 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mersana Therapeutics
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company's long-term goal is profitability, and its current focus is clinical trials. This chart shows the investment in the platform, which enables the precise delivery of powerful drugs to cancer cells, increasing efficacy and reducing side effects.
Profit of companies in the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Its platform enables the delivery of more potent antitumor agents directly to cancer cells. This graph illustrates the overall trend in oncology, where ADC technology is one of the hottest areas, promising highly effective treatments.
Overall market profit
Mersana Therapeutics is developing antibody-drug conjugates (ADCs) for cancer treatment. Its success depends on the results of clinical trials. However, the overall economic backdrop, as illustrated by this chart, influences the willingness of investors and large pharmaceutical companies to finance new technological platforms in oncology.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mersana Therapeutics
Mersana Therapeutics develops antibody-drug conjugates (ADCs)—"smart bombs" that deliver powerful chemotherapy directly to cancer cells, particularly in the treatment of ovarian cancer. This chart shows analysts' assessment of the commercial potential of this advanced oncology platform.
%20profit%20of%20the%20company%20Mersana%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mersana-Therapeutics&v=1772647261726 "Graph of future (projected) profit of the company Mersana Therapeutics")
Future (predicted) profit of companies in the market segment - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs)—"smart bombs" that deliver powerful chemotherapeutic agents directly to cancer cells. The company focuses on the treatment of ovarian cancer and other solid tumors. This chart shows profitability projections for the biotech sector, reflecting the potential of ADCs as one of the most promising areas in oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-women&v=1772647261732 "Graph of future (predicted) profits of companies in a market segment - Cancer women")
Future (predicted) profit of the market as a whole
Mersana Therapeutics is developing antibody-drug conjugates (ADCs) for the treatment of cancer. The company's funding is contingent on the success of clinical trials and overall investor interest in biotechnology. This schedule, reflecting overall market expectations, impacts the availability of capital for companies at the forefront of the fight against cancer.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647261830 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mersana Therapeutics
Mersana Therapeutics is developing a new class of cancer drugs known as antibody-drug conjugates. This chart shows the valuation of its scientific platform. The high valuation reflects the company's hopes that its drugs will be effective treatments, particularly for women's cancers.
P/S market segment - Cancer women
Mersana Therapeutics, Inc. is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. This chart shows the average revenue estimate in the biotech sector. It provides an indication of how highly investors value the potential revenue from Mersana's innovative platform, which is designed to precisely deliver potent drugs to cancer cells.
P/S of the market as a whole
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. Their technology enables precise delivery of a potent toxin to cancer cells, increasing efficacy and reducing side effects. This chart provides a general revenue metric that can be used to assess how investors value innovative oncology platforms.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mersana Therapeutics
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, primarily ovarian cancer. This chart reflects investor expectations for its innovative platform. The assessment is based on the potential of its drug candidates to offer more effective treatment for patients with limited therapeutic options.
%20P%2FS%20Mersana%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mersana-Therapeutics&v=1772647261893 "The graph of the company's future (projected) P/S Mersana Therapeutics")
Future (projected) P/S of the market segment - Cancer women
Mersana Therapeutics is developing a new class of drugs—antibody-drug conjugates (ADCs)—for the treatment of cancer, particularly ovarian cancer. This approach delivers chemotherapy directly to tumor cells. This chart shows how the market views its innovative ADC platform compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20women&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-women&v=1772647261909 "Future (projected) P/S market segment graph - Cancer women")
Future (projected) P/S of the market as a whole
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. This graph, reflecting the biotech investment climate, directly impacts Mersana. Investors' willingness to invest in long-term, risky projects, which increases during periods of optimism, is vital for funding the company's research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647261969 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mersana Therapeutics
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. This chart reflects revenue from strategic alliances and partnerships with major pharmaceutical companies. It shows the financial support for the innovative platform, which delivers potent chemotherapeutic agents directly to tumor cells.
Sales of companies in the market segment - Cancer women
Mersana Therapeutics, Inc. is a biotechnology company developing a novel class of antibody-drug conjugates (ADCs) for the treatment of cancer. Its business is segmented into various development programs, each based on its proprietary platforms, such as Dolaflexin. This chart depicts the cash flows associated with one of its lead candidates.
Overall market sales
Mersana Therapeutics is a biotechnology company developing antibody-drug conjugates (ADCs) for the treatment of cancer, with a particular focus on ovarian cancer. This technology enables the delivery of potent drugs directly to tumor cells. Mersana's success depends on clinical data and may provide new treatment options for patients with difficult-to-treat cancers.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mersana Therapeutics
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. Its future sales forecast reflects market expectations for the success of its clinical programs, particularly in ovarian cancer. This is a bet that its innovative ADC platform will enable the development of more effective and safer targeted therapies.
%20sales%20of%20the%20company%20Mersana%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mersana-Therapeutics&v=1772647262131 "Schedule of future (projected) sales of the company Mersana Therapeutics")
Future (projected) sales of companies in the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. This chart illustrates expectations for the entire women's oncology sector. It helps assess the progress being made in developing targeted therapies and the demand analysts predict for new treatments in this field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-women&v=1772647262296 "Schedule of future (projected) sales of companies in the market segment - Cancer women")
Future (projected) sales of the market as a whole
Mersana Therapeutics develops innovative antibody-drug conjugates for the treatment of cancer. The company's funding is dependent on the success of its research and the overall biotech market. This chart of overall sales forecasts reflects the economic sentiment that influences investment in this sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647262366 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mersana Therapeutics
Mersana Therapeutics is a clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. This chart reflects its financial trajectory, where high clinical trial costs are an investment in the development of more effective and safer anticancer drugs.
Market segment marginality - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs) for targeted cancer therapy, particularly ovarian cancer. The effectiveness of their platform lies in its ability to precisely deliver potent drugs to tumors. The chart below compares their operating model to other oncology companies working on ADCs.
Market marginality as a whole
Mersana Therapeutics is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancer. This technology delivers chemotherapy precisely to tumor cells. This graph shows the profitability of mature businesses, while MRSN's value is determined by the potential of its innovative ADC platform and clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Mersana Therapeutics
Mersana Therapeutics specializes in developing next-generation antibody-drug conjugates (ADCs) for cancer treatment. This chart shows the company's growing team of scientists. This increase is directly related to the expansion of its clinical pipeline and the development of new, more effective ADC technologies.
Share of the company's employees Mersana Therapeutics within the market segment - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs)—"smart bombs"—for the treatment of cancer, particularly ovarian cancer. The creation of such complex drugs requires a large scientific team. This chart shows the team's contributions to one of the most promising areas in oncology.
Number of employees in the market segment - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. This chart reflects the workload in the women's oncology sector. The growing number of researchers in this field indicates a high demand for more effective and less toxic treatments, which is the goal of Mersana's ADC technology.
Number of employees in the market as a whole
Mersana Therapeutics develops antibody-drug conjugates for the treatment of cancer. Its development is determined not by the general state of the labor market, but by scientific progress. The data in this chart reflects macroeconomics, while Mersana prioritizes patents and successful clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mersana Therapeutics (MRSN)
Mersana Therapeutics, Inc. is developing antibody-drug conjugates (ADCs) for the treatment of cancer. This is a complex and promising technology. The high market capitalization per employee in this chart demonstrates that investors highly value the company's scientific platform and its pipeline, which was developed by a small team of scientists.
%20of%20the%20company%20Mersana%20Therapeutics%20(MRSN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mersana-Therapeutics-MRSN&v=1772647262563 "Chart of market capitalization per employee (in thousands of dollars) of the company Mersana Therapeutics (MRSN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer women
Mersana Therapeutics is developing a new class of antibody-drug conjugates (ADCs) for the treatment of cancer, particularly in women. In oncology, the cost per employee is the market valuation of their scientific platform and clinical candidates. This chart shows how highly investors value their innovative approach to targeted therapy.
%20by%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-women&v=1772647262573 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer women")
Market capitalization per employee (in thousands of dollars) for the overall market
Mersana Therapeutics is developing a new class of drugs—antibody-drug conjugates (ADCs)—to more precisely deliver chemotherapy to cancer cells. The chart reflects the market's high appreciation for this innovative oncology platform, which promises to make cancer treatment more effective and less toxic.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647262585 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mersana Therapeutics (MRSN)
Mersana Therapeutics is a biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer treatment. These are "smart bombs" that deliver chemotherapy directly to tumors. This graph (negative) shows R&D intensity. It measures how much capital the company "burns" per scientist to advance its ADC candidates through clinical trials.
%20Chart%20Mersana%20Therapeutics%20(MRSN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mersana-Therapeutics-MRSN&v=1772647262592 "Company Profit Per Employee (in thousands of dollars) Chart Mersana Therapeutics (MRSN)")
Profit per employee (in thousands of dollars) in the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer, particularly ovarian cancer. In this complex field of biotechnology, value is created by the scientific team. This chart shows how productive their ADC platform is in creating value and serves as a comparison with other oncology companies.
%20in%20the%20market%20segment%20-%20Cancer%20women&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-women&v=1772647262630 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer women")
Profit per employee (in thousands of dollars) for the market as a whole
Mersana Therapeutics (MRSN) is a biotech R&D company developing antibody-drug conjugates (ADCs) for cancer treatment. Negative profit per employee is the norm for the clinical stage. The chart shows the "cost" of the team of scientists working on this complex technology platform, which does not yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647262673 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mersana Therapeutics (MRSN)
Mersana Therapeutics is developing a new class of oncology drugs—antibody-drug conjugates (ADCs). While in the clinical stage, its revenue depends on partner fees. This graph will show the future commercial success of its ADC platform in cancer treatment.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mersana-Therapeutics-MRSN&v=1772647262690 "Sales chart per company employee Mersana Therapeutics (MRSN)")
Sales per employee in the market segment - Cancer women
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer (such as ovarian cancer). This chart compares revenue per employee (R&D) to the industry average. It reflects how productive their scientific platform (ADC) is in generating valuable candidates and attracting partnerships.
Sales per employee for the market as a whole
Mersana Therapeutics (MRSN) is a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancer, primarily ovarian cancer. It is a clinical-stage R&D company. Revenue comes not from sales but from major partnerships (such as with J&J and GSK). This chart shows the value (revenue) generated by their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Mersana Therapeutics (MRSN)
Mersana Therapeutics (MRSN) is a biotech company developing antibody-drug conjugates (ADCs) for cancer treatment. This technology for delivering chemotherapy directly to tumors is highly sought after, but also highly competitive. This chart shows the number of investors betting that Mersana's drugs will underperform compared to competitors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mersana-Therapeutics-MRSN&v=1772647262737 "Short Shares Chart for the Company Mersana Therapeutics (MRSN)")
Shares shorted by market segment - Cancer women
Mersana Therapeutics develops antibody-drug conjugates (ADCs)—"smart bombs" that deliver chemotherapy directly to cancer cells, specifically targeting ovarian cancer. This chart shows the odds against the ADC sector. It reflects concerns about drug toxicity and the high level of competition in this hot field.
Shares shorted by the overall market
Mersana Therapeutics is developing antibody-drug conjugates (ADCs) for cancer treatment. This chart illustrates the overall market pessimism. For a biotech company that has experienced R&D setbacks, rising fear means zero risk tolerance. Investors are not giving second chances and are selling shares at the slightest uncertainty.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mersana Therapeutics (MRSN)
Mersana Therapeutics develops antibody-drug conjugates (ADCs) for the treatment of cancer, primarily ovarian cancer. The company's shares are binary and dependent on trial data. This oscillator clearly shows moments of "overheating" (above 70) before data releases and deep "oversold" (below 30) following news of the FDA trial suspension.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mersana-Therapeutics-MRSN&v=1772647262908 "RSI 14 indicator chart for the company's stock Mersana Therapeutics (MRSN)")
RSI 14 Market Segment - Cancer women
Mersana Therapeutics is a biopharmaceutical company specializing in next-generation antibody-drug conjugates (ADCs). Its technology (Immunosynthen) targets cancer, particularly ovarian cancer. This chart shows the overall sentiment in the female oncology biotech sector. It helps distinguish the dynamics of MRSN from the overall hype or decline in the biotech sector.
RSI 14 for the overall market
Mersana (MRSN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRSN (Mersana Therapeutics)
Mersana Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for the treatment of cancer. This chart shows the average target price. Analysts' estimates are based on clinical data for its lead candidates and the safety of its platform compared to competitors in the hot ADC field.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRSN-Mersana-Therapeutics&v=1772647263144 "A chart showing analyst consensus forecasts for the expected stock price. MRSN (Mersana Therapeutics)")
The difference between the consensus estimate and the actual stock price MRSN (Mersana Therapeutics)
Mersana Therapeutics is a biotech company pioneering the development of next-generation adjuvant conjugates (ADCs) for precisely delivering chemotherapy to cancer cells. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the R&D portfolio after past setbacks.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRSN-Mersana-Therapeutics&v=1772647263200 "A chart showing the difference between the consensus forecast and the actual stock price. MRSN (Mersana Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Cancer women
Mersana Therapeutics is a biotech company and a pioneer in the field of ADCs (antibody-drug conjugates). It develops "smart bombs" that deliver chemotherapy directly to tumors. This chart shows general expectations for the oncology sector. It reflects whether experts believe the ADC market will boom.
Analysts' consensus forecast for the overall market share price
Mersana Therapeutics is a biotech company specializing in the development of antibody-drug conjugates (ADCs)—"smart bombs" that deliver chemotherapy directly to cancer cells. This chart shows the overall market "risk appetite." For Mersana, a clinical-stage company in the hot ADC sector, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mersana Therapeutics
Mersana Therapeutics is ADC 2.0. They are developing a new generation of smart chemotherapies (antibody-drug conjugates) that are designed to be more effective and less toxic, primarily for the treatment of ovarian cancer. This graph is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Cancer women
Mersana Therapeutics (MRSN) is an oncology company specializing in the development of next-generation antibody-drug conjugates (ADCs), primarily for the treatment of ovarian cancer and other gynecological cancers. The chart shows the segment average index, helping investors assess how Mersana's platform compares to the average in the competitive ADC space.
The AKIM Index for the overall market
Mersana Therapeutics is a company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story, overcoming clinical challenges, compares to overall economic trends in oncology.
